2Speidl WS, Graf S, Hornykewycz S, et al. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease [ J ]. Am Heart J, 2002,144 ( 3 ) : 449-455.
3Hou FF, Owen WF Jr. Beta 2-microglobulin amyloidosis:role of monocytes/macrophages[J]. Curr Opin Nephrol Hypertens, 2002, 11 (4) :417-421.
4Kalousova M, Zima T, Tesar V, et al. Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients [I]. Blood Purif, 2002,20(6) :531-536.
5Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: Moving an inflammatory hypothesis toward consensus. J Am Coli Cardiol2007; 49: 2129-38.
6Bisoendial RJ, Boekholdt SM, Vergeer M, Stroes ES, Kastelein JJ. C-reactive protein is a mediator of cardiovascular disease. Eur Heart J 2010; 31: 2087 -91.
7Grad E, Danenberg HD. C-reactive protein and atherothrombosis: Cause or effect? Blood Rev 2013; 27: 23-9.
8Sundgren NC, Zhu W, Yuhanna IS, Chambliss KL, Ahmed M, Tanigaki K, et al. Coupling of Fcy receptor I to Fcy receptor lib by src kinase mediates c-reactive protein impairment of endothelial function. Circ Res 2011; 109: 1132-40.
9Raaz-Schrauder D, Ekici AB, Klinghammer L, Stumpf C, Achenbach S, Herrmann M, et al. The proinflammatory effect of c-reactive protein on human endothelial cells depends on the Fcy lIa genotype. Thromb Res 2014; 133: 426-32.
10Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317- 25.
